Clinuvel Commences US Phase III Trial of SCENESSE® in Rare Light and UV Disorder
5/22/2012 12:09:46 PM
More...
|
Swiss Insurers Agree to Reimburse Clinuvel's SCENESSE® for Rare Disease
4/26/2012 11:41:55 AM
More...
|
Clinuvel Files European Marketing Authorisation Application for SCENESSE® (afamelanotide)
2/6/2012 6:14:37 AM
More...
|
Clinuvel Announces Positive Results From Pivotal European Phase III Study: Endpoints Demonstrate Clinically Relevant Treatment Effect of Afamelanotide
12/19/2011 3:03:58 PM
More...
|
Clinuvel Announces Positive Results of First Phase II US Study of SCENESSE® in Orphan Disease Erythropoietic Protoporphyria (EPP)
11/3/2011 7:33:15 AM
More...
|
EMA Acknowledges Clinuvel’s Novel Drug Filing in Europe in 2011
5/12/2011 9:38:35 AM
More...
|
Clinuvel Release: FDA Allows World First Vitiligo Drug Trial
3/2/2011 2:53:28 PM
More...
|
Clinuvel Completes First Phase II US Study
2/9/2011 9:10:36 AM
More...
|
Clinuvel Release: Successful Drug Trial Results for Light Intolerant 'Shadow Jumpers'
7/13/2010 9:02:33 AM
More...
|
Clinuvel Novel UV Protecting Drug Delivered By The Picogram
7/8/2010 10:50:13 AM
More...
|
|